Moving Beyond HDL Cholesterol, HDL Function as a Coronary Disease Biomarker

超越 HDL 胆固醇，HDL 作为冠心病生物标志物

• 批准号: 8488256
• 负责人: Anand Kumar Rohatgi
• 金额: $ 11.77万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-01 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8488256
• 关键词: African American; Antiatherogenic; Applications Grants; Area; Atherosclerosis; Biological; Biological Factors; Biological Markers; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Cause of Death; Cholesterol; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Coronary heart disease; Development Plans; Disease; Elements; Ensure; Enzymes; Epidemiologic Studies; Epidemiology; Event; Exhibits; Faculty; Female; General Population; Genetic Polymorphism; Genotype; Goals; Heart; High Density Lipoprotein Cholesterol; High Density Lipoproteins; Human; Inflammation; Insulin Resistance; LDL Cholesterol Lipoproteins; Laboratories; Laboratory Research; Lead; Link; Lipids; Master' s Degree; Measurement; Measures; Mediating; Mentors; Mentorship; Metabolic; Metabolism; Nicotinic Acids; Obesity; Paraoxonase 1; Pathway interactions; Peripheral; Pharmaceutical Preparations; Phenotype; Plasma; Population; Population Heterogeneity; Population Sciences; Positioning Attribute; Preparation; Prevention; Program Development; Publications; Race; Reporting; Research; Research Personnel; Role; Sampling; Scientist; Techniques; Testing; Tissues; Training; Translational Research; Variant; Vascular Diseases; Woman; aryldialkylphosphatase; base; biobank; cardiovascular disorder epidemiology; cardiovascular disorder risk; career; career development; clinically relevant; disorder risk; heart disease risk; human NOS3 protein; improved; interest; lipid metabolism; macrophage; novel; nutrition; oxidation; population based; prospective; public health relevance; randomized trial; sex; skills; therapeutic target; torcetrapib; vascular inflammation

DESCRIPTION (provided by applicant): My career goal is to become an independent investigator focused on applying laboratory-based techniques assessing HDL functions to large human populations. I have focused thus far on acquiring clinical research skills allowing me to pursue broad epidemiologic assessments of novel biomarkers in improving coronary disease risk prediction in the Dallas Heart Study, culminating in several first-author publications and completion of a Master's Degree in Clinical Sciences. I am now positioned to apply this expertise to the biomarker area that I am most interested in-HDL function. My immediate research goals are based on evidence that directly assessing HDL functions in human studies may lead to better targeting of HDL-modifying therapies aimed at reducing cardiovascular disease (CVD) risk. These focused career goals mandate a mentored career development pathway to acquire the necessary laboratory-based skill sets to gain independence as a translational clinician investigator in the specific field of HDL metabolism and CVD. Key elements of my career development plan include: 1) multi-disciplinary mentorship: Dr. Philip Shaul as primary mentor, an established translational scientist, and Dr. James de Lemos as co-mentor, my current mentor in population science research and director of the Dallas Heart Study biomarker core; 2) coursework in laboratory and clinical research; 3) direct laboratory training in HDL function studies (Philip Shaul, UTSW; Dan Rader, Penn); and preparation for R01 grant application. The objective of this proposal is to systematically investigate two major HDL functions in relation to CHD in the general population. My central hypothesis is that plasma measurements of HDL-mediated macrophage-specific cholesterol efflux and HDL activation of eNOS (HDL functions) will vary significantly according to race, sex, and metabolic status and inversely correlate with vascular disease independent of HDL-C. I plan to test this hypothesis by prospectively measuring HDL function in an extensively phenotyped existing biobank of human plasma collected from the Dallas Heart Study (n=2,971; 50% African American; 50% women) to pursue the following three specific aims: 1) identify the biological factors influencing variation n HDL functions across a diverse population; 2) determine the associations of paraoxonase-1 (PON-1) activity and genotype with HDL functions; 3) comprehensively investigate the role of HDL functions in predicting CHD. These studies are anticipated to have an important positive impact, because the comprehensive assessment of the cardiovascular epidemiology of HDL function will rapidly facilitate clinical investigations targeting functional HDL pathways rather than simple concentration of HDL-C to reduce CHD risk. UT Southwestern combines extraordinary epidemiologic and translational research opportunities and faculty development programs that will ensure the PI's successful clinical research career, specifically the Dallas Heart Study led by Dr. Helen Hobbs, the Center for Nutrition led by Dr. Scott Grundy, and the Department of Clinical Sciences led by Dr. Milton Packer.

描述（由申请人提供）：我的职业目标是成为一名独立的研究者，专注于应用基于实验室的技术来评估高密度脂蛋白的功能。到目前为止，我一直专注于获得临床研究技能，使我能够在达拉斯心脏研究中对新型生物标志物进行广泛的流行病学评估，以改善冠状动脉疾病的风险预测，最终发表了几篇第一作者的论文，并完成了临床科学硕士学位。我现在的定位是将这些专业知识应用于我最感兴趣的生物标志物领域——hdl功能。我的近期研究目标是基于直接评估人体研究中HDL功能的证据，这可能会导致更好地靶向旨在降低心血管疾病（CVD）风险的HDL修饰疗法。这些专注的职业目标要求指导的职业发展途径，以获得必要的实验室为基础的技能，以获得在HDL代谢和心血管疾病特定领域的独立转化临床医生研究者。我职业发展计划的关键要素包括：1)多学科指导：Philip Shaul博士是我的主要导师，他是一位知名的转化科学家，James de Lemos博士是我的共同导师，他是我目前在人口科学研究方面的导师，也是达拉斯心脏研究生物标志物核心的主任；2)实验室和临床研究课程；3)直接进行实验室培训